[go: up one dir, main page]

AU2001287007A1 - Reagents and methods for the diagnosis of cmv dissemination - Google Patents

Reagents and methods for the diagnosis of cmv dissemination

Info

Publication number
AU2001287007A1
AU2001287007A1 AU2001287007A AU8700701A AU2001287007A1 AU 2001287007 A1 AU2001287007 A1 AU 2001287007A1 AU 2001287007 A AU2001287007 A AU 2001287007A AU 8700701 A AU8700701 A AU 8700701A AU 2001287007 A1 AU2001287007 A1 AU 2001287007A1
Authority
AU
Australia
Prior art keywords
reagents
diagnosis
methods
cmv dissemination
dissemination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001287007A
Inventor
Daniel J. Dairaghi
Brian E. Mcmaster
Thomas J. Schall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AU2001287007A1 publication Critical patent/AU2001287007A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001287007A 2000-08-30 2001-08-30 Reagents and methods for the diagnosis of cmv dissemination Abandoned AU2001287007A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22919100P 2000-08-30 2000-08-30
US60/229,191 2000-08-30
PCT/US2001/027269 WO2002017969A2 (en) 2000-08-30 2001-08-30 Reagents and methods for the diagnosis of cmv dissemination

Publications (1)

Publication Number Publication Date
AU2001287007A1 true AU2001287007A1 (en) 2002-03-13

Family

ID=22860168

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001287007A Abandoned AU2001287007A1 (en) 2000-08-30 2001-08-30 Reagents and methods for the diagnosis of cmv dissemination

Country Status (3)

Country Link
US (1) US20020193374A1 (en)
AU (1) AU2001287007A1 (en)
WO (1) WO2002017969A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7025968B2 (en) 2000-08-30 2006-04-11 Chemocentryx, Inc. CMV vaccines
AU2001287043A1 (en) * 2000-08-30 2002-03-13 Chemocentryx, Inc. Modulators of us28 (chemokines) for treating cytomegalovirus infections
AU2002242085A1 (en) 2001-02-02 2002-08-19 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US6821998B2 (en) * 2001-08-30 2004-11-23 Chemocentryx, Inc. Arylamines as inhibitors of chemokine binding to US28
EP1393728A1 (en) * 2002-08-30 2004-03-03 Vrije Universiteit Inverse agonists acting at virus-encoded G protein-coupled receptors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4172197A (en) * 1996-09-10 1998-04-02 Pharmacia & Upjohn Company 8-hydroxy-7-substituted quinolines as anti-viral agents
US7025968B2 (en) * 2000-08-30 2006-04-11 Chemocentryx, Inc. CMV vaccines
AU2001287043A1 (en) * 2000-08-30 2002-03-13 Chemocentryx, Inc. Modulators of us28 (chemokines) for treating cytomegalovirus infections

Also Published As

Publication number Publication date
WO2002017969A3 (en) 2003-05-22
WO2002017969A2 (en) 2002-03-07
US20020193374A1 (en) 2002-12-19
WO2002017969A9 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
AU5724000A (en) Anastomosis system and methods for use
AU2001288249A1 (en) Biosensors and methods for their use
AU2001255655A1 (en) Treatment analysis systems and methods
AU4063400A (en) Catalytic trap and methods of making and using the same
AU2001250965A1 (en) Method and system for clinical knowledge management
AU2001245288A1 (en) Overhanging form system and method of using the same
AU2002239740A1 (en) Nanolithography methods and products therefor and produced thereby
AU6420201A (en) System for workflow analysis and response
AU2002223743A1 (en) Means for detecting pathological transformation of the APP protein and their uses
AU2001249444A1 (en) Methods and compositions for the simultaneous detection of multiple analytes
AU2002367947A1 (en) Chemical and biological hazard sensor system and methods thereof
AU2002210868A1 (en) Reaction measurement method and system
AU2002320156A1 (en) Risk evaluation system and methods
AU3760400A (en) Methods and reagents for the diagnosis and treatment of multiple sclerosis
AU2001255580A1 (en) Methods and compositions for the diagnosis of schizophrenia
AU2001287007A1 (en) Reagents and methods for the diagnosis of cmv dissemination
AU2001241714A1 (en) Micro-label biological assay system
AU2001292468A1 (en) Methods and means of rna analysis
AU2002227019A1 (en) Cashcalling and voicemining system
AUPQ820900A0 (en) Warning and guidance system
AU2316400A (en) An ultrasound system and methods utilizing same
HUP0303286A3 (en) Compositions and methods for the discovery and selection of biological information
AU2001257164A1 (en) Methods and compositions for the diagnosis of schizophrenia
IL155526A0 (en) Compositions and methods for the discovery and selection of biological information
AU2001259127A1 (en) Methods and composition for the diagnosis of schizophrenia